To our knowledge, this is the first study to evaluate a PI3K/mTOR inhibitor in GBM using multiple distinct and previously characterized glioma cell lines and glioma-initiating stem cells is an important consideration when attempting to identify susceptible genotypes because of the genetic heterogeneity of GBM. This evidence concerns the gene MTOR and glioblastoma.